DalarginДаларгин

From enkephalin design to tissue-injury research

Dalargin connects endogenous opioid-peptide biology with the experimental question of tissue resistance to stress. Its D-Ala substitution and terminal arginine distinguish it from natural Leu-enkephalin. The 1999 receptor study shows why sequence, assay and formulation must remain attached to mechanistic claims. It is not interchangeable with Semax, Selank or tissue-derived bioregulators.

The Titov–Vinogradov–Bespalova citation from 1985 explicitly frames Dalargin as cytoprotective. Gastrointestinal, cardiovascular and stress research became different branches of that idea. A coherent historical rationale does not establish effectiveness across all those settings.

Mine-blast hearing injury: an unusual human report

RU2323019C1 describes combined Dalargin and electropuncture in blast-related hearing injury. It is patent case material, not a modern randomized trial. Its proposed hypoxia and microcirculation rationale is a hypothesis; the contribution of Dalargin cannot be isolated. The research record preserves the reported outcomes and the patent’s internal numerical inconsistency.

Severe hypoxia: animal survival, not altitude protection

Kalinin’s 2000 dissertation investigates rats in a pressure chamber, comparing ordinary administration with experimental erythrocyte-carrier delivery. The reported persistence at later testing times is a question for replication, not evidence that the peptide remains in circulation for days or that a person can safely tolerate extreme altitude. Survival tables, the early time notation and original scans need reconciliation.

Stress, resuscitation and clinical trauma

Frantsuzova’s animal dissertation compares Dalargin, Picamilon and Mildronate. These are separate approaches, not an established three-agent combination. Razgonov’s dissertation abstract documents a different Dalargin–Mildronate resuscitation research program; claims of synergy need original interaction analyses.

The 2023 prospective trauma comparison is a more recent human source. Its biochemical and organ-dysfunction findings must be read alongside comparable mortality and infections, unequal groups and unresolved allocation. It does not justify an improvement-in-survival claim.

Historical combinations and delivery are separate questions

Archived proposals include Dalargin with ketorolac during prolonged evacuation, multicomponent hemorrhagic-shock care, and Bemitil, Dalargin and acupuncture for chronic hearing loss. None establishes a general-purpose stack. Topical burn formulations and erythrocyte carriers must also be distinguished from ordinary systemic Dalargin.

Bibliography and remaining research gaps

Further acquisition priorities include the Slepushkin–Zoloev–Vinogradov–Titov neuropeptide monograph (1988), Zakharova’s immobilization-stress dissertation (1988), early Zakusov–Yasnetsov opioid/hypoxia experiments, and the original military-medical anti-ischemia paper. Bibliographic details and original texts need verification before study-level findings can be entered.

Burns/DSIP comparisons, radiation/Actovegin comparisons, hypothermia and gastrointestinal clinical reports remain additional retrieval leads. Mentioning these branches does not establish positive results. Blood-pressure effects and delivery-specific safety require dedicated appraisal; peripheral action is not a safety guarantee.